FDA Guides On Pathway For Competitive Generic Therapies
Executive Summary
Draft guidance on the approval pathway for competitive generic therapies (CGTs) has been published by the FDA in the agency’s latest move to advance generic drug competition.
You may also be interested in...
Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Amneal Launches Amicar Rival With CGT Exclusivity
After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.
Amneal’s Amicar Rival Gets CGT Exclusivity
After receiving a CGT designation by the FDA for its generic version of Amicar, Amneal gets 180 days of exclusivity.